SAN DIEGO, Dec. 31, 2018 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet…Original Article
FDA Grants Priority Review Designation for Heron Therapeutics’ NDA for HTX-011, a Non-Opioid for Postoperative Pain Management
